List of Lupkynis drug patents

Lupkynis is owned by Aurinia.

Lupkynis contains Voclosporin.

Lupkynis has a total of 2 drug patents out of which 0 drug patents have expired.

Lupkynis was authorised for market use on 22 January, 2021.

Lupkynis is available in capsule;oral dosage forms.

Lupkynis can be used as treatment of patients with active lupus nephritis.

Drug patent challenges can be filed against Lupkynis from 2025-01-22.

The generics of Lupkynis are possible to be released after 07 December, 2037.

LUPKYNIS Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 2025-01-22

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

43

United States

22

Japan

10

Canada

9

European Union

7

Australia

7

Korea, Republic of

7

China

5

Israel

4

South Africa

4

Denmark

4

Austria

4

Russia

4

Norway

4

Germany

4

Croatia

4

Brazil

4

Portugal

4

Spain

4

Poland

3

Mexico

3

Hong Kong

3

Morocco

3

Colombia

YU

3

Yugoslavia

3

Taiwan, Province of China

3

Ecuador

3

Tunisia

3

New Zealand

2

Slovenia

2

Uruguay

2

Argentina

2

Malaysia

2

ME

IB

1

IB

1

Belgium

1

Lithuania

1

Singapore

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in